Spondyloarthritis & psoriatic arthritis
Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study
Authors' conclusion
Mortality risk in PsA in Sweden was about 10% higher than in the general population, driven by excess comorbidity and with increased risks mainly in women and patients with longer disease duration.
Study context
- Population
- Adults with PsA from the Swedish National Patient Register and matched general population, follow-up 2007–2018
- Exposure
- PsA vs matched general population comparators
- Outcome
- All-cause mortality
Methodological detailsmatched 1:5 on sex, county and age, matched Cox proportional hazard regression
- Matched 1:5 on sex, county and age
- Matched Cox proportional hazard regression
Main finding
As reported in the abstract
Each group vs comparator-subjectsEstimate (95% CI)
PsA
HR 1.11(1.07–1.16)
PsA
IRR 1.18(1.13–1.22)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| All-cause mortality in women (subgroup) | 1.23 (1.16–1.30) | |
| All-cause mortality with longer time since diagnosis (subgroup) | 1.18 (1.12–1.25) | |
| 0.512Hazard ratio (log scale) |
IRR of death by age
- Significantly increased for all ages except below 40 years, numerically highest for ages 40-59 years
All-cause mortality adjusted for comorbidity
- Elevated mortality risk in PsA disappeared
Causes of death
- Similar among PsA cases/comparator-subjects; CVD and malignancy the leading causes
Original publication
Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study. Ann Rheum Dis. Published 12 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →